证券日报网讯金城医药（300233）9月29日在互动平台回答投资者提问时表示，目前二期厂房土建已基 本建设完成，公司将结合厂房装修进度、产品管线布局等合理规划并逐步推进。 ...

截至9月29日收盘，转基因概念下跌0.17%，位居概念板块跌幅榜前列，板块内，金城医药、神农种 业、国投丰乐等跌幅居前，股价上涨的有6只，涨幅居前的有新安股份、华邦健康、托普云农等，分别 上涨3.89%、1.80%、0.78%。 转基因概念资金流出榜 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 300233 | 金城医药 | -4.49 | 4.06 | -3903.99 | | 000998 | 隆平高科 | -0.31 | 0.85 | -1357.17 | | 600596 | 新安股份 | 3.89 | 1.75 | -1100.98 | | 600313 | 农发种业 | -0.48 | 1.39 | -806.02 | | 002170 | 芭田股份 | 0.75 | 3.16 | -744.40 | | 002041 | 登海种业 | 0.22 | 0.65 | -551.30 | | 300189 | 神农种业 | -0.69 | 5.15 | -550.34 | | 0020 ...

截至9月29日收盘，维生素概念下跌0.18%，位居概念板块跌幅榜前列，板块内，*ST苏吴跌停，金城医 药、华恒生物、*ST中基等跌幅居前，股价上涨的有36只，涨幅居前的有吉林敖东、科源制药、海欣股 份等，分别上涨6.69%、1.93%、1.83%。 今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 金属锌 | 3.68 | 猪肉 | -0.54 | | 金属镍 | 3.65 | 兵装重组概念 | -0.52 | | 金属铅 | 3.61 | 培育钻石 | -0.44 | | 期货概念 | 3.32 | 维生素 | -0.18 | | 钠离子电池 | 3.08 | 转基因 | -0.17 | | 金属钴 | 3.02 | 共享单车 | -0.14 | | 固态电池 | 2.96 | 乳业 | -0.12 | | 盐湖提锂 | 2.78 | 养鸡 | -0.12 | | PVDF概念 | 2.76 | 玉米 | -0.11 | | 钛白粉概念 | 2.73 | 宠物经济 | -0.11 | （文章来源：证券时报网） ...

Group 1 - The company, Jincheng Pharmaceutical, has submitted a patent application for the preparation method and application of nicotine salt compounds through its subsidiary [1] - The patent application is currently under review [1]

Group 1 - The company Jin Cheng Pharmaceutical reported that as of September 20, 2025, the total number of shareholders is 28,237 [2]

Core Viewpoint - Jincheng Pharmaceutical announced that its subsidiary has received a notification for the approval of the chemical raw material drug, Mirabegron, which is primarily used for treating overactive bladder (OAB) conditions such as urinary incontinence, urgency, and frequency [1] Group 1: Product Approval and Market Impact - Mirabegron is a selective β-3 adrenergic receptor agonist, and its approval indicates compliance with national technical standards for raw material drug review [1] - The approval allows for production and sales in the domestic market, enhancing the company's product line in raw materials and improving its competitiveness in the chemical raw material drug sector [1] Group 2: Market Data and Trends - Currently, there are 18 companies in China with Mirabegron approval status A on the raw material drug registration platform [1] - According to IMS data, global consumption of Mirabegron raw materials is projected to be 57.91 tons in 2022, 63.05 tons in 2023, and 69.79 tons in 2024 [1] - Global sales of Mirabegron formulations are expected to reach $3.286 billion in 2022, $3.420 billion in 2023, and $3.536 billion in 2024 [1]

Core Viewpoint - The company has submitted a patent application for a method and application of nicotine salt compounds, which aims to address the issue of nicotine release not matching human metabolism, particularly the insufficient release in later stages [1] Company Summary - The subsidiary of the company has filed a patent application for the preparation method and application of nicotine salt compounds, which is currently under review [1]

Core Viewpoint - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing application of the chemical raw material drug Mirabegron [1] Group 1 - The approval notification number is 2025YS00837 [1] - The drug approved is a chemical raw material named Mirabegron [1]

Core Viewpoint - Jincheng Pharmaceutical's subsidiary has received approval for the marketing application of Mirabegron, a selective β-3 adrenergic receptor agonist, which is primarily used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Company Summary - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has recently received a notification from the National Medical Products Administration regarding the approval of the marketing application for the chemical raw material drug Mirabegron [1] - Mirabegron is indicated for the treatment of overactive bladder (OAB), addressing conditions like urinary incontinence, urgency, and frequency [1]

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) has received approval from the National Medical Products Administration for its chemical raw material drug, Mirabegron, which is a selective β-3 adrenergic receptor agonist used to treat overactive bladder (OAB) symptoms such as urinary incontinence, urgency, and frequency [1] Group 1 - The company’s wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., is responsible for the approval of Mirabegron [1] - Mirabegron is specifically indicated for the treatment of overactive bladder (OAB) [1] - The approval marks a significant milestone for the company in expanding its product portfolio in the pharmaceutical market [1]